Lu Cai Selected Research

Metallothionein

1/2022	Whole life exposure to low dose cadmium alters diet-induced NAFLD.
1/2021	Cardiac metallothionein overexpression rescues diabetic cardiomyopathy in Akt2-knockout mice.
1/2020	Metallothionein induction attenuates the progression of lung injury in mice exposed to long-term intermittent hypoxia.
12/2019	Neonatal murine engineered cardiac tissue toxicology model: Impact of dexrazoxane on doxorubicin induced injury.
10/2019	Metallothionein Protects the Heart Against Myocardial Infarction via the mTORC2/FoxO3a/Bim Pathway.
1/2019	Combination of Broccoli Sprout Extract and Zinc Provides Better Protection against Intermittent Hypoxia-Induced Cardiomyopathy Than Monotherapy in Mice.
1/2019	Protection against diabetic cardiomyopathy is achieved using a combination of sulforaphane and zinc in type 1 diabetic OVE26 mice.
1/2019	The adaptive immune role of metallothioneins in the pathogenesis of diabetic cardiomyopathy: good or bad.
10/2018	Nrf2 expression and function, but not MT expression, is indispensable for sulforaphane-mediated protection against intermittent hypoxia-induced cardiomyopathy in mice.
3/2018	Reappraisal of metallothionein: Clinical implications for patients with diabetes mellitus.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Lu Cai Research Topics

Disease

57	Inflammation (Inflammations) 02/2022 - 12/2008
49	Fibrosis (Cirrhosis) 02/2022 - 12/2004
41	Diabetic Cardiomyopathies 02/2022 - 01/2003
32	Neoplasms (Cancer) 01/2022 - 03/2003
26	Diabetic Nephropathies (Diabetic Nephropathy) 12/2021 - 02/2004
25	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2020 - 12/2009
23	Obesity 02/2022 - 12/2006
22	Type 2 Diabetes Mellitus (MODY) 01/2022 - 12/2008
21	Insulin Resistance 01/2020 - 02/2011
19	Hyperglycemia 04/2022 - 06/2002
17	Hypoxia (Hypoxemia) 01/2022 - 08/2007
16	Body Weight (Weight, Body) 01/2022 - 01/2003
16	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 01/2002
16	Cardiomyopathies (Cardiomyopathy) 01/2020 - 01/2003
16	Diabetes Complications 01/2019 - 04/2004
12	Cardiomegaly (Heart Hypertrophy) 12/2020 - 04/2013
11	Hypertrophy 02/2022 - 07/2010
9	Cardiotoxicity 03/2021 - 01/2002
8	Hypertension (High Blood Pressure) 01/2022 - 01/2009
8	Breast Neoplasms (Breast Cancer) 01/2021 - 03/2013
7	Diabetes Mellitus 11/2021 - 10/2005
6	Ischemia 04/2022 - 01/2003
6	Non-alcoholic Fatty Liver Disease 01/2022 - 01/2016
6	Fatty Liver 01/2021 - 01/2015
6	Myocardial Infarction 10/2019 - 01/2002
6	Metabolic Syndrome (Dysmetabolic Syndrome X) 12/2018 - 12/2008
5	Necrosis 06/2021 - 01/2003
5	Atherosclerosis 03/2021 - 01/2003
5	Wounds and Injuries (Trauma) 07/2018 - 01/2008
4	Heart Diseases (Heart Disease) 01/2021 - 01/2012
4	Heart Failure 07/2019 - 01/2014
4	Proteinuria 01/2019 - 04/2007
4	Prostatic Neoplasms (Prostate Cancer) 01/2018 - 07/2011
4	Hyperlipidemias (Hyperlipidemia) 01/2016 - 02/2004
3	Pulmonary Arterial Hypertension 01/2022 - 01/2020
3	Myocardial Ischemia (Ischemic Heart Diseases) 03/2021 - 12/2014
3	Hepatocellular Carcinoma (Hepatoma) 01/2021 - 03/2018
3	Kidney Diseases (Kidney Disease) 01/2021 - 01/2015
3	B-Cell Lymphoma (Lymphoma, B Cell) 12/2020 - 01/2017
3	Pulmonary Fibrosis (Fibrosing Alveolitis) 10/2020 - 07/2011
3	Chronic Disease (Chronic Diseases) 01/2020 - 01/2003

Drug/Important Bio-Agent (IBA)

35	MetallothioneinIBA 01/2022 - 03/2003
30	Streptozocin (Streptozotocin)FDA Link 01/2021 - 01/2003
29	Glucose (Dextrose)FDA LinkGeneric 04/2022 - 06/2002
26	AntioxidantsIBA 06/2021 - 01/2003
26	ZincIBA 12/2020 - 01/2006
25	Proteins (Proteins, Gene)FDA Link 01/2022 - 01/2003
23	LipidsIBA 10/2021 - 02/2004
18	sulforaphaneIBA 02/2022 - 01/2012
13	Insulin (Novolin)FDA Link 01/2021 - 06/2002
12	fibroblast growth factor 21IBA 01/2020 - 01/2011
11	CadmiumIBA 03/2022 - 10/2013
11	Pharmaceutical PreparationsIBA 01/2021 - 02/2004
10	CollagenIBA 02/2022 - 07/2005
10	Plasminogen Activator Inhibitor 1IBA 01/2021 - 04/2007
9	Messenger RNA (mRNA)IBA 01/2021 - 02/2010
8	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 02/2022 - 01/2003
8	Transcription Factors (Transcription Factor)IBA 01/2022 - 02/2011
8	Reactive Oxygen Species (Oxygen Radicals)IBA 12/2019 - 01/2009
8	Connective Tissue Growth FactorIBA 03/2017 - 02/2004
7	CytokinesIBA 01/2022 - 01/2003
7	p38 Mitogen-Activated Protein KinasesIBA 01/2022 - 01/2010
7	Fibroblast Growth Factor 1 (FGF-1)IBA 01/2022 - 03/2007
7	EnzymesIBA 01/2021 - 01/2003
7	Phosphotransferases (Kinase)IBA 01/2019 - 11/2006
7	Therapeutic UsesIBA 03/2015 - 01/2008
6	Fibronectins (Fibronectin)IBA 02/2022 - 01/2013
6	Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA 02/2022 - 12/2009
6	Caspase 3 (Caspase-3)IBA 06/2021 - 06/2002
6	Fibroblast Growth Factors (Fibroblast Growth Factor)IBA 01/2021 - 01/2010
6	IronIBA 12/2019 - 01/2008
6	CurcuminIBA 01/2019 - 06/2014
6	Angiotensin IIIBA 01/2018 - 07/2011
6	Small Interfering RNA (siRNA)IBA 02/2014 - 01/2010
5	Fenofibrate (CiL)FDA LinkGeneric 01/2020 - 04/2016
5	Chelating AgentsIBA 12/2019 - 01/2008
5	Biomarkers (Surrogate Marker)IBA 05/2019 - 11/2016
5	Histones (Histone)IBA 01/2019 - 01/2014
4	Atrial Natriuretic Factor (ANF)IBA 02/2022 - 04/2013
4	Transforming Growth Factors (Transforming Growth Factor)IBA 12/2021 - 01/2014
4	Biological ProductsIBA 01/2019 - 04/2004
4	Sirtuin 1IBA 03/2018 - 12/2014
4	Blood Glucose (Blood Sugar)IBA 01/2016 - 01/2014
4	Hydrogen Peroxide (Hydroperoxide)FDA LinkGeneric 01/2012 - 03/2007
3	Environmental Pollutants (Pollutants, Environmental)IBA 03/2022 - 03/2021
3	Advanced Glycation End ProductsIBA 06/2021 - 12/2004
3	MicroRNAs (MicroRNA)IBA 01/2021 - 11/2013
3	Malondialdehyde (Propanedial)IBA 01/2021 - 01/2010
3	MetalsIBA 01/2021 - 03/2017
3	Cisplatin (Platino)FDA LinkGeneric 01/2021 - 08/2013
3	Fatty Acids (Saturated Fatty Acids)IBA 01/2021 - 01/2019
3	Triglycerides (Triacylglycerol)IBA 01/2021 - 01/2003
3	PalmitatesIBA 01/2021 - 09/2016
3	ArsenicIBA 09/2019 - 07/2013
3	ResveratrolIBA 01/2019 - 10/2016
3	4-O-methylhonokiolIBA 01/2019 - 01/2014

Therapy/Procedure

22	Therapeutics 01/2022 - 01/2009
9	Drug Therapy (Chemotherapy) 03/2021 - 03/2013
8	Intraperitoneal Injections 01/2020 - 01/2003
4	Radiotherapy 12/2021 - 01/2014